| (Values in U.S. Thousands) | Oct, 2025 | Jul, 2025 | Apr, 2025 | Jan, 2025 | Oct, 2024 |
| Sales | 8,961,000 | 8,578,000 | 8,927,000 | 8,292,000 | 8,403,000 |
| Sales Growth | +4.46% | -3.91% | +7.66% | -1.32% | +6.17% |
| Net Income | 1,374,000 | 1,040,000 | 1,056,000 | 1,294,000 | 1,269,000 |
| Net Income Growth | +32.12% | -1.52% | -18.39% | +1.97% | +21.67% |
Medtronic Inc (MDT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Medtronic, Inc. acquired Ireland-based Covidien plc. The acquisition resulted in the formation of a new holding company incorporated in Ireland - Medtronic plc. The company currently generates revenues from four major segments - namely Cardiovascular Portfolio, Medical Surgical Portfolio, Neuroscience Portfolio and Diabetes. The Cardiovascular Portfolio, formerly reported as the Cardiac and Vascular Group, includes the Cardiac Rhythm & Heart Failure, Structural Heart & Aortic and Coronary & Peripheral Vascular divisions. The Medical Surgical Portfolio, formerly reported as the Minimally Invasive Therapies Group, includes the Surgical Innovations and the Respiratory, Gastrointestinal & Renal divisions. Neuroscience consists of Cranial & Spinal Technologies, Specialty The Neuroscience Portfolio, formerly reported as the Restorative Therapies Group, includes the Cranial & Spinal Technologies, Specialty Therapies, and Neuromodulation divisions.
Fiscal Year End Date: 04/30